top of page
YT Channel banner.jpg

Which ASX Stocks Held Up Best as the Market Fell From Its 10 November 2026 High?

Writer: Christopher Hall
Christopher Hall
3 days ago
18 min read

Updated: 11 minutes ago

Written by Christopher Hall, AdvDipFP | Authorised Representative, AFSL 526688 | Updated November 2026

On 17 November 2026, a week after the market's recent high on 10 November, the S&P/ASX 200 fell 1.79% and the All Ordinaries fell 1.83% — and 26 liquid ASX stocks still rose, led by Ion Video, Clover Corporation and Technology One. A stock that rises while the index falls is showing relative strength, and this article starts a dated record of which ASX stocks do it on each decline from the 10 November 2026 high. Christopher Hall, Authorised Representative (AFSL 526688), names the stocks, sources the figures and sets out the screen, so each later reading can be compared with this one.

This is a new series. It runs from a different high to the September 2026 series, which tracked declines from an earlier peak in the down-day relative strength series, and the two are cross-referenced below.

Update — 19 November 2026: Reading 2, on a day the S&P/ASX 200 fell 1.04%, has been added below. It covers the three groups that led (healthcare, defensive income, and housing and consumer cyclicals), the market context noted by Christopher Hall, and the overlap with earlier readings. Four stocks have now shown relative strength in both readings of this series.

What Did the ASX Do After Its 10 November 2026 High?

On 17 November 2026 the S&P/ASX 200 (XJO) closed at 8,883.19, down 161.51 points or 1.79% from 9,044.70, and the All Ordinaries (XAO) closed at 8,997.28, down 168.12 points or 1.83% from 9,165.40. Both fell by more than 1% on the day, which is the standing threshold this series uses to count a decline, and the fall came exactly one week after the 10 November 2026 high that anchors the series.

Relative strength during a decline is a stock rising, or falling less than the index, on a day the index falls. Reading it on a day of broad selling matters because a stock that finds buyers while most of the market is sold is showing demand that does not depend on the market's direction.

Which ASX Stocks Rose When the Market Fell on 17 November 2026?

Twenty-six ASX stocks rose on 17 November 2026, a day the S&P/ASX 200 fell 1.79%, while trading more than $250,000 in value and without a move large enough to point to a one-off catalyst. The table ranks them by that day's gain.

Table — ASX stocks that rose against the market on 17 November 2026 (XJO −1.79%, XAO −1.83%), ranked by gain:

#

ASX

Company

Change, 17 Nov 2026

Value traded, 17 Nov 2026

1

IOV

Ion Video

+20.14%

$1.00M

2

CLV

Clover Corporation

+13.07%

$0.49M

3

TNE

Technology One

+8.86%

$85.4M

4

IVR

Investigator Silver

+8.70%

$1.48M

5

IMR

Imricor Medical Systems

+8.18%

$0.64M

6

29M

29Metals

+7.84%

$2.11M

7

EML

EML Payments

+6.25%

$0.87M

8

MVF

Monash IVF Group

+4.11%

$0.26M

9

PPC

Peet Limited

+4.08%

$0.64M

10

CU6

Clarity Pharmaceuticals

+3.56%

$6.91M

11

HLS

Healius

+3.45%

$4.02M

12

CTT

Cettire

+3.28%

$0.33M

13

BGL

Bellevue Gold

+2.92%

$12.4M

14

XRO

Xero

+2.38%

$133.2M

15

FCL

Fineos Corporation

+2.30%

$14.2M

16

APA

APA Group

+1.78%

$49.3M

17

ALD

Ampol

+1.65%

$59.3M

18

ORG

Origin Energy

+1.62%

$55.7M

19

WGN

Wagners Holding Company

+1.56%

$1.27M

20

RRL

Regis Resources

+1.52%

$26.5M

21

FGG

Future Generation

+1.27%

$0.48M

22

COH

Cochlear

+1.15%

$31.3M

23

RMD

ResMed

+1.11%

$90.6M

24

VEA

Viva Energy Group

+1.08%

$16.8M

25

RF1

Regal Investment Fund

+1.03%

$0.34M

26

WHF

Whitefield Industrials

+1.00%

$0.59M

Source: Iress — ASX stock price and market value data, 17 November 2026 close vs prior close, compiled by Christopher Hall, Finer Market Points. Screen: market value traded above $250,000 that day; moves of 30% or more excluded as likely company-specific catalysts; no price floor.

Among the stocks in these tables that traded more than $50 million on 17 November 2026, Technology One (ASX: TNE) posted the largest gain at 8.86%, on turnover of about $85.4 million. Xero (ASX: XRO) rose 2.38% on $133.2 million and ResMed (ASX: RMD) rose 1.11% on $90.6 million, the two heaviest turnovers in the list. This series records the move and does not assess its cause, so some of the larger gains may reflect company announcements rather than steady demand.

Three of the 26 are funds rather than operating companies: Regal Investment Fund (RF1), Future Generation (FGG) and Whitefield Industrials (WHF). They cleared the same screen and are kept in the table, but they are a separate story from stock-level relative strength, because a fund's price follows the portfolio it holds rather than a single company's demand.

How Is This Relative Strength Series Measured?

Each reading in this series compares a stock's close on a day the S&P/ASX 200 and All Ordinaries both fall by more than 1% with its close the day before, using Iress price and market value data compiled by Christopher Hall. The 17 November 2026 reading was built from three Iress gainers tables — large-cap, mid-cap and small-cap, 25 rows each, 75 rows in all — and 26 stocks cleared the screen.

The screen has three parts:

  1. The stock rose on the day — it closed above the prior close while the index fell.

  2. Value traded above $250,000 that day — turnover is the only liquidity test, so a stock priced under $1 is not excluded if it trades enough, and one priced above $1 is excluded if it does not.

  3. A move of 30% or more is excluded — a gain that size is treated as a likely company-specific catalyst, not relative strength.

This is a partial record, not a census. Only the rows in the three tables were reviewed, so a rising stock that sat outside the top 25 of its table is not captured. Each reading in the series is updated on the day of a decline, not on a fixed weekly schedule, and the figures are one-day close-to-close moves, not weekly returns.

Why Is Mayne Pharma's 87% Gain Not Counted as Relative Strength?

Mayne Pharma (ASX: MYX) rose 87.23% on 17 November 2026 on turnover of about $34.6 million — the largest gain in the data — and it is excluded from the table. The move is associated with a takeover offer for the company, a specific corporate event of the kind the 30% exclusion exists to separate out, and the terms of the offer are not assessed here. A takeover-driven repricing is a headline event, not the independent demand relative strength is meant to describe.

Why Did No Small-Cap Stock Qualify on 17 November 2026?

None of the 25 small-cap rows traded more than $250,000 in value on 17 November 2026, so none qualified. The highest turnovers in that table were Step One Limited (ASX: STP) at about $181,000, Imagion Biosys (ASX: IBX) at about $144,000 and Black Rock Mining (ASX: BKT) at about $111,000. Several of the table's gains were very large — 100%, 58%, 50% and 33% — but a price move on that little turnover can reflect a handful of trades, so the screen does not count it.

Have These Stocks Shown Relative Strength Before?

Nine of the 26 stocks also appear in the September 2026 series, and three of them — Viva Energy (VEA), Healius (HLS) and ResMed (RMD) — have now shown relative strength on three dated declines across the two series. That is a cross-series count, not a count within this series, which has only one reading so far.

Table — stocks from the 17 November 2026 reading that also appeared in the earlier series:

ASX

Company

Earlier-series readings (daily change)

17 Nov 2026

VEA

Viva Energy Group

8 Sep +2.05%; 11 Sep +2.36%

+1.08%

HLS

Healius

8 Sep +1.09%; 15 Sep +7.06%

+3.45%

RMD

ResMed

8 Sep +0.06%; 15 Sep +2.85%

+1.11%

CU6

Clarity Pharmaceuticals

8 Sep +4.41%

+3.56%

IVR

Investigator Silver

8 Sep +3.77%

+8.70%

ORG

Origin Energy

8 Sep +0.89%

+1.62%

ALD

Ampol

8 Sep +0.66%

+1.65%

COH

Cochlear

10 Sep +1.68%

+1.15%

CTT

Cettire

1 Oct +19.15%

+3.28%

Source: Iress — ASX stock price and market value data, 8, 10, 11 and 15 September, 1 October and 17 November 2026 daily closes vs prior close, compiled by Christopher Hall, Finer Market Points. The 8 September list also applied a market-cap eligibility filter that the 17 November reading does not, and the 11 and 15 September readings were days when the S&P/ASX 200 fell by less than 1%, included as part of a cluster of closely spaced declines. The comparison is therefore indicative, not like-for-like.

The earlier readings, and the repeaters they produced, are set out in full in the down-day relative strength series. A name recurring across two different highs and several declines is a longer record than one reading gives, though it remains a short sample and past appearances are no guarantee the pattern continues on the next decline. ResMed has since added a fourth dated decline on 19 November 2026, covered in Reading 2 below.

The stocks that led the first reading in the down-day relative strength series — Computershare (ASX: CPU), Insurance Australia Group (ASX: IAG), GrainCorp (ASX: GNC), Elders (ASX: ELD), Challenger (ASX: CGF), Telstra Group (ASX: TLS), Suncorp Group (ASX: SUN) and Supply Network (ASX: SNL) — are at or near recent or 52-week highs, and are leading the market, according to Christopher Hall's observation. That is the practical use of this series: a stock that rises on a day the index falls is a candidate for closer research, and relative strength during a decline helps narrow a long list down to the stocks that may become the next market leaders. It is a filter for further study, not a forecast, and a stock appearing in a reading does not mean it will lead the market.

The FMP Momentum Profile — published daily and accessible to FMP YouTube Momentum Profile members — tracks the market conditions that form the context for thematic articles like this one. Members receive early access to the educational data discussed in each weekly session.

Reading 2: Which ASX Stocks Rose When the Market Fell on 19 November 2026?

On 19 November 2026 the S&P/ASX 200 fell 1.04% and the All Ordinaries fell 1.07%, and the leading gainers in each size band were concentrated in healthcare, defensive income stocks and housing-linked consumer stocks. Both indices fell by more than 1%, narrowly, so the day counts as a decline in this series and is its second reading from the 10 November 2026 high.

Reading 2 uses a different data cut to Reading 1. It is built from the 20 largest gainers in each of three size bands — large caps above A$10 billion, mid caps from A$2 billion to A$10 billion, and small and micro caps below A$2 billion — 60 stocks in all, measured close to close. Value traded was not in this data, so the $250,000 turnover screen could not be applied, while the 30% exclusion was: DXN (ASX: DXN) rose 30.30% and is excluded as a likely company-specific catalyst. Three of the 60 are funds rather than operating companies — iShares S&P 500 ETF (IVV), L1 Long Short Fund (LSF) and AI Private Opportunities Trust (AIX).

This is a partial, unscreened record, not a census. The large-cap cut-off was +0.44% and the mid-cap cut-off +0.69%, and the small-cap gains in particular are unchecked for liquidity — on 17 November none of the 25 small-cap rows reviewed passed the turnover test.

What Was Moving the Australian Market on 19 November 2026?

According to Christopher Hall's market notes, Australia's unemployment rate printed at 4.9% on 19 November 2026, above expectations and up from 4.7% in September, and the Australian dollar fell as bond markets moved to price a lower RBA cash rate next year. The September figure is from the Australian Bureau of Statistics; the October print, the currency move and the rate-expectations pricing are Christopher Hall's market notes for the day.

Christopher Hall's reading is that these moves fed through to equities unevenly. A lower expected cash rate tends to favour interest-rate-sensitive groups such as property trusts, housing-linked companies and consumer stocks, while a weaker labour market tends to support defensive groups such as healthcare and telecommunications, and a lower Australian dollar lifts the Australian-dollar value of overseas earnings, which is relevant to healthcare companies with large offshore revenue. That is context for the pattern below, not a proven cause: one day's cluster is consistent with that reading but does not establish it, and the S&P/ASX 200 still closed 1.04% lower.

Which Sectors Led When the Market Fell on 19 November 2026?

Healthcare was the largest group among the 19 November 2026 leaders with nine of the 60 stocks, followed by defensive income with nine and housing and consumer cyclicals with six — 24 of the 60 in the three groups. The table lists each stock with its earlier appearances in this series and in the September series.

Table — Reading 2 leaders in healthcare, defensive income, and housing and consumer cyclicals, 19 November 2026 (XJO −1.04%, XAO −1.07%), ranked by gain within each group:

Group

ASX

Company

Change, 19 Nov 2026

Earlier appearances

Healthcare

IMM

Immutep

+13.04%

11 Sep +27.27%

Healthcare

AVH

AVITA Medical

+8.05%

—

Healthcare

SHL

Sonic Healthcare

+6.28%

—

Healthcare

RHT

Resonance Health

+5.26%

—

Healthcare

4DX

4DMedical

+5.12%

15 Sep +8.72%

Healthcare

FPH

Fisher & Paykel Healthcare

+2.91%

—

Healthcare

RMD

ResMed

+2.56%

8 Sep +0.06%; 15 Sep +2.85%; 17 Nov +1.11%

Healthcare

RHC

Ramsay Health Care

+1.55%

8 Sep +0.26%

Healthcare

COH

Cochlear

+0.46%

10 Sep +1.68%; 17 Nov +1.15%

Defensive income

DXS

Dexus

+1.99%

—

Defensive income

TLS

Telstra Group

+1.55%

8 Sep +3.01%; 15 Sep

Defensive income

CHC

Charter Hall Group

+1.28%

—

Defensive income

SPK

Spark New Zealand

+1.11%

—

Defensive income

SGP

Stockland

+0.90%

—

Defensive income

HDN

HomeCo Daily Needs REIT

+0.85%

—

Defensive income

CNU

Chorus

+0.74%

—

Defensive income

TPG

TPG Telecom

+0.74%

—

Defensive income

SCG

Scentre Group

+0.57%

—

Housing and consumer cyclicals

JHX

James Hardie

+3.79%

—

Housing and consumer cyclicals

APE

Eagers Automotive

+3.01%

10 Sep +3.09%

Housing and consumer cyclicals

RWC

Reliance Worldwide

+2.65%

8 Sep +0.48%

Housing and consumer cyclicals

FBU

Fletcher Building

+2.39%

—

Housing and consumer cyclicals

JBH

JB Hi-Fi

+2.00%

15 Sep +2.85%

Housing and consumer cyclicals

HVN

Harvey Norman

+0.69%

—

Source: Finer Market Points ASX stock performance data, 19 November 2026 close vs prior close, compiled by Christopher Hall; earlier appearances from Iress daily readings on 8, 10, 11 and 15 September and 17 November 2026. Value traded was not available for this reading, so the $250,000 turnover screen was not applied. Group labels are Finer Market Points' editorial classification; "defensive income" means property trusts and telecommunications companies.

Healthcare: nine stocks, with five of the top 20 large-cap places. Sonic Healthcare's +6.28% was the largest large-cap gain, and four medtech and biotech small caps followed — Immutep +13.04%, AVITA Medical +8.05%, Resonance Health +5.26% and 4DMedical +5.12%. Healthcare also supplied six of the 26 qualifying stocks on 17 November (Healius, Imricor Medical Systems, Clarity Pharmaceuticals, Monash IVF Group, Cochlear and ResMed), and ResMed and Cochlear rose on both days. A lower Australian dollar is one point of context for companies with large offshore revenue such as ResMed and Cochlear; it does not explain the small-cap names, whose gains are unchecked for turnover.

Defensive income: nine stocks, none of which appeared on 17 November. Five property trusts — Dexus +1.99%, Charter Hall Group +1.28%, Stockland +0.90%, HomeCo Daily Needs REIT +0.85% and Scentre Group +0.57% — and four telecommunications companies — Telstra Group +1.55%, Spark New Zealand +1.11%, Chorus +0.74% and TPG Telecom +0.74% — rose, in a narrow range from +0.57% to +1.99%. Both groups are income-style holdings whose prices are typically sensitive to bond yields, which fits Christopher Hall's reading of the move in rate expectations. Telstra Group is the one repeat, having shown relative strength on 8 and 15 September.

Housing and consumer cyclicals: six stocks, with larger gains than the defensive group. James Hardie +3.79%, Eagers Automotive +3.01%, Reliance Worldwide +2.65%, Fletcher Building +2.39%, JB Hi-Fi +2.00% and Harvey Norman +0.69% — three building products companies, a car retailer and two household retailers — are the kind of companies typically sensitive to the interest-rate outlook. Three of the six (Eagers Automotive, Reliance Worldwide and JB Hi-Fi) had also appeared in the September series.

Outside the three groups, the largest mid-cap gains were in technology and digital infrastructure — NEXTDC +4.30%, Life360 +4.03% and Megaport +3.50% — and Lynas Rare Earths rose 3.40% among the energy and resources names, with Omega Oil & Gas +21.01% and Lakes Blue Energy +15.09% among the unchecked small caps. Travel and aviation also featured: Corporate Travel Management +7.55%, Qantas +2.43%, Auckland Airport +0.95% and Virgin Australia +0.75%.

How Do the 19 November 2026 Leaders Overlap With Earlier Readings?

Four stocks have appeared in both readings of this series — ResMed, Cochlear, Clover Corporation and Ion Video — and 22 of the 60 Reading 2 stocks appeared in an earlier reading in either series. The within-series count is the sharper test of persistence because both readings share one starting high; the cross-series count is indicative, because the readings differ in screen and data source.

Leadership rotated between the two readings. Only 4 of the 26 stocks that qualified on 17 November appeared in the 19 November top-20 lists. The 17 November energy, gold and silver names — Ampol, Origin Energy, Viva Energy, 29Metals, Investigator Silver, Bellevue Gold and Regis Resources — were not among them, nor were Technology One and Xero, so the overlap was confined to healthcare names and two small caps.

Table — Reading 2 stocks with three or more dated declines in total, or that repeated within this series (19 November 2026):

ASX

Company

Earlier dated readings

19 Nov 2026

Dated declines in total

RMD

ResMed

8 Sep +0.06%; 15 Sep +2.85%; 17 Nov +1.11%

+2.56%

4

MP1

Megaport

8 Sep +0.12%; 10 Sep +4.25%; 15 Sep +2.69%

+3.50%

4

CTD

Corporate Travel Management

8 Sep +0.91%; 10 Sep +6.50%; 11 Sep +15.49%

+7.55%

4

TLS

Telstra Group

8 Sep +3.01%; 15 Sep

+1.55%

3

COH

Cochlear

10 Sep +1.68%; 17 Nov +1.15%

+0.46%

3

360

Life360

11 Sep +1.60%; 15 Sep +5.02%

+4.03%

3

NHC

New Hope

8 Sep +0.94%; 15 Sep +3.03%

+1.76%

3

CLV

Clover Corporation

17 Nov +13.07%

+8.11%

2

IOV

Ion Video

17 Nov +20.14%

+4.43%

2

Source: Iress — ASX stock price and market value data, 8, 10, 11 and 15 September and 17 November 2026 daily closes vs prior close, and Finer Market Points ASX stock performance data, 19 November 2026, compiled by Christopher Hall, Finer Market Points. The 8 September list applied a market-cap eligibility filter, the 11 and 15 September readings were days the S&P/ASX 200 fell by less than 1%, and the 19 November reading is not screened for turnover, so the comparison is indicative, not like-for-like. Telstra Group's 15 September daily change is not shown.

A further 12 stocks had one earlier appearance — Ramsay Health Care, Immutep, 4DMedical, Appen, Omega Oil & Gas, Eagers Automotive, JB Hi-Fi, News Corp, Brambles, Reliance Worldwide, L1 Long Short Fund and Chrysos — and DXN, which showed relative strength on 8 and 11 September, is excluded from Reading 2 under the 30% rule. Megaport, Corporate Travel Management and ResMed are the three names now on four dated declines, which remains a short sample.

Why Does Relative Strength During a Decline Matter for Momentum Trading?

Relative strength — a core concept in William O'Neil's CAN SLIM methodology — treats a stock holding firm or advancing while the broader index declines as a leading indicator of future outperformance, not merely a curiosity. The logic is that a stock still finding buyers on a day most of the market is selling has shown a source of demand independent of the general market, which is the quality momentum traders look for in a prospective new leader.

The full 5-step screening method is set out in Finer Market Points' relative strength guide; this article supplies dated, worked readings of the idea, and that one supplies the method. The sector-level version of the same question, updated weekly, is tracked in the weekly ASX sector leadership record.

How Will This Series Be Updated?

Each later decline from the 10 November 2026 high is added to this article as a dated reading, using the same screen. From the second reading onward the article will track which stocks repeat within the series, the within-series count being the sharper test of persistence because every reading shares one starting high and one screen. Reading 2, on 19 November 2026, is the first with a within-series comparison: four stocks — ResMed, Cochlear, Clover Corporation and Ion Video — appeared in both readings.

Conclusion

A second reading on 19 November 2026 found the S&P/ASX 200 down 1.04% and the All Ordinaries down 1.07%, with the leading gainers clustered in healthcare, defensive income and housing-linked consumer stocks, a session Christopher Hall's notes associate with a 4.9% unemployment print above expectations, a lower Australian dollar and lower RBA rate expectations. ResMed, Cochlear, Clover Corporation and Ion Video have now shown relative strength in both readings.

On 17 November 2026, one week after the market's recent high, the S&P/ASX 200 fell 1.79% and 26 liquid ASX stocks rose against it, led by Ion Video at +20.14% and by Technology One at +8.86% on $85.4 million of turnover. Mayne Pharma's 87.23% gain was excluded as a takeover-linked event, and no small-cap stock cleared the $250,000 turnover screen. Viva Energy, Healius and ResMed have now shown relative strength on three dated declines across this series and the September one. The FMP Momentum Profile and the Finer Market Points weekly session recordings — where market conditions like those discussed in this article are reviewed in real time — are accessible to FMP YouTube Momentum Profile members.

This article draws on publicly available research data compiled for the Finer Market Points editorial program. The FMP Momentum Profile and the Finer Market Points weekly session recordings — where ASX momentum stocks and the market conditions covered in thematic articles like this one are reviewed in real time — are accessible to FMP YouTube Momentum Profile members. Members receive early access to the educational data that forms the basis of articles like this one. For information on FMP YouTube Momentum Profile membership, visit the FMP YouTube membership page.

Remember that past performance is no guarantee of future results, and all trading involves risk.

Frequently Asked Questions

Which ASX stocks rose when the market fell on 17 November 2026?

Twenty-six liquid ASX stocks rose on 17 November 2026, a day the S&P/ASX 200 fell 1.79% and the All Ordinaries fell 1.83%. The largest gains were Ion Video (+20.14%), Clover Corporation (+13.07%), Technology One (+8.86%), Investigator Silver (+8.70%) and Imricor Medical Systems (+8.18%), each with more than $250,000 in value traded.

Why were no small-cap stocks in the 17 November 2026 list?

None of the 25 small-cap rows reviewed traded more than $250,000 in value that day, so none passed the liquidity screen. The highest turnover in that table was about $181,000 (Step One Limited), and a large percentage move on that little trading can reflect a few trades rather than genuine demand.

Why was Mayne Pharma's 87% gain excluded from the relative strength list?

Mayne Pharma (ASX: MYX) rose 87.23% on 17 November 2026, a move associated with a takeover offer for the company. Any gain of 30% or more is treated as a likely company-specific catalyst, and a takeover-driven repricing is a corporate event rather than the independent demand relative strength describes.

Is one day of relative strength during a market fall a reliable signal?

It is one input among several, not a standalone signal. William O'Neil's CAN SLIM methodology treats relative strength during weakness as a leading indicator of potential outperformance, but a single day is a short read — the pattern carries more weight when it repeats across several declines and is confirmed by other momentum criteria.

How does this series differ from the September 2026 relative strength series?

This series tracks declines from the market's 10 November 2026 high, while the September series tracks declines from an earlier peak. Each uses the same screen, and the two are cross-referenced where a stock appears in both.

How will the 10 November 2026 high series be updated?

Each later decline from the 10 November 2026 high is added as a dated reading, using the same screen: the stock rose, value traded above $250,000, and any move of 30% or more excluded. From the second reading the article will also track which stocks show relative strength on more than one decline within the series. The second reading, on 19 November 2026, is now included, and four stocks have shown relative strength in both readings.

Which sectors led when the ASX fell on 19 November 2026?

On 19 November 2026 the S&P/ASX 200 fell 1.04% and the All Ordinaries fell 1.07%. Among the top 20 gainers in each size band, healthcare (nine stocks, led by Immutep +13.04% and Sonic Healthcare +6.28%), defensive income (nine property trust and telecommunications stocks) and housing and consumer cyclicals (six stocks, led by James Hardie +3.79%) were the largest groups. According to Christopher Hall's market notes, the day followed a 4.9% unemployment print above expectations, a lower Australian dollar and lower RBA rate expectations; the cluster is consistent with that context, not proof of its cause.

Which stocks showed relative strength on both 17 and 19 November 2026?

Four stocks appeared in both readings: ResMed (+1.11% and +2.56%), Cochlear (+1.15% and +0.46%), Clover Corporation (+13.07% and +8.11%) and Ion Video (+20.14% and +4.43%). The 19 November reading was not screened for turnover, so its figures are not like-for-like with the screened 17 November reading.

About the Author

Christopher Hall, AdvDipFP, is an Authorised Representative (AFSL 526688) and the editorial lead at Finer Market Points, covering ASX-listed momentum stocks and market data for an Australian trading audience. Read more on the author's profile page.

Sources

#

Source

Type

1

Iress. S&P/ASX 200 (XJO) and All Ordinaries (XAO) index data, 17 November 2026 close vs prior close, compiled by Christopher Hall, Finer Market Points.

Market data

2

Iress. ASX stock price and market value data (large-cap, mid-cap and small-cap gainers tables), 17 November 2026 close vs prior close, compiled by Christopher Hall, Finer Market Points.

Market data

3

Iress. ASX stock price and market value data, 8, 10, 11 and 15 September and 1 October 2026 daily closes vs prior close (earlier series), compiled by Christopher Hall, Finer Market Points.

Market data

4

O'Neil, W. How to Make Money in Stocks (2009) — relative strength as a component of the CAN SLIM methodology.

Published research

5

Finer Market Points. ASX stock performance data (top 20 gainers per size band) and S&P/ASX 200 and All Ordinaries percentage changes, 19 November 2026 close vs prior close, compiled by Christopher Hall, Finer Market Points.

Market data

6

Australian Bureau of Statistics. Labour Force, Australia (September 2026 release, 15 October 2026, and October 2026 release, 19 November 2026).

Official statistics

7

Hall, C. Market notes on the 19 November 2026 unemployment print, the Australian dollar and RBA rate expectations, Finer Market Points.

Editorial commentary

Related Finer Market Points Educational Resources

This content is for educational purposes only and does not constitute financial advice. Past performance is no guarantee of future results.

The information, opinions and other materials appearing on this website are of a general nature only and shall not be construed as advice. Finer Market Points Pty Ltd, CAR 1304002, AFSL 526688, ABN 87 645 284 680. This general information is educational only and not financial advice, recommendation, forecast or solicitation. This is not taxation advice. Rose Bay Equities accepts no responsibility for the accuracy or completeness of the information, opinions or other materials provided on or accessible through this website. This website has not been prepared with reference to your individual financial or personal circumstances. You should not rely on any advice on this website without first seeking appropriate professional, financial and legal advice. Further, where Rose Bay Equities makes third party material available or accessible through this website you acknowledge that Rose Bay Equities is a distributor and not a publisher of that content and that its editorial control is limited to the selection of those materials to make available. We accept no liability for any loss or damages arising from use. Authors and presenters may hold positions in discussed companies and investment products.

Recent Posts

See All

Comments


bottom of page